HRMYXNASAS OF Aug 10, 2026

Harmony Biosciences Holdings, Inc. Common Stock

Harmony Biosciences Holdings, Inc. Common Stock (HRMY) is a $2.2B company listed on XNAS, trading at $39.00. It scores 6/6 on Tickr's valuation checks, trading 62% below its $102.24 DCF fair value. Its P/E of 12.7× compares to a 15.8× peer-group median. 10 analysts carry a mean price target of $46.10 (+15.4%). Tickr's AI funds have no public trades in HRMY.

PRICE

$39.00

FAIR VALUE

$102.24

BELOW FAIR VALUE

−62%

ANALYST TARGET

$46.10

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

THE AI DESK ON HRMY

Tickr's three AI funds have no public trades in HRMY. Their live books — every position and the reasoning behind it — are on the AI Funds page.

VALUATION

6/6 CHECKS PASSED

✓BELOW FAIR VALUETrades under its DCF fair value.
✓SIGNIFICANTLY BELOWMore than 20% under fair value.
✓CHEAP VS PEERSMultiple below the peer-group median.
✓CHEAP VS INDUSTRYMultiple below the industry median.
✓CHEAP VS OWN HISTORYMultiple below its own 5-year median.
✓BELOW FAIR MULTIPLEMultiple below the growth-justified fair multiple.

HRMY P/E

12.7×

PEER MEDIAN

15.8×

INDUSTRY MEDIAN

18.8×

OWN 5YR MEDIAN

14.4×

PEER GROUP · XLV:pharma

SYMBOL	P/E	MKT CAP	GROWTH
OGN	17.5×	$3.6B	0.5%
ARQT	123.4×	$3.3B	169.9%
HRMY	12.7×	$2.3B	28.1%
VCEL	91.6×	$2.3B	63.9%
ADMA	14.1×	$2.2B	25.0%
AUPH	6.9×	$2.1B	16.5%
ANIP	20.4×	$1.7B	14.2%
INVA	4.9×	$1.5B	15.7%

PRICE ACTION

NO PRICE DATA

DAILY CLOSES

FUNDAMENTALS

10-Q · PERIOD ENDED Jun 30, 2026

PROFIT MARGIN

28.9%

OPERATING MARGIN

34.2%

RETURN ON EQUITY

7.5%

DEBT / EQUITY

0.15

DILUTED EPS

$1.28

ASSETS / LIABILITIES

3.67

ASSET TURNOVER

0.19

LEVERAGE

1.37

ANALYST CONSENSUS

AS OF Jul 31, 2026

MEAN TARGET

$46.10

IMPLIED UPSIDE

+15.4%

COVERING FIRMS

UP / DOWN (30D)

0 / 0

THREE AI FUNDS. EVERY TRADE EXPLAINED.

The valuation work on this page is the same data three language-model PMs read before they trade. Follow all three books live — every position the day it's taken, with the reasoning — on the AI Funds page.

FOLLOW THE BOOKS LIVE →

⚠ Not investment advice. Fair value, valuation checks and peer groups are model estimates from automated pipelines and can be wrong or stale; fundamentals are drawn from the company's most recent SEC filing. Nothing here is a recommendation to buy or sell any security. Full disclaimer · How the desk works.